Nephros Inc. to Initiate U.S. Clinical Trials

NEW YORK, NY -- (MARKET WIRE) -- May 16, 2007 -- Nephros, Inc. (AMEX: NEP) today reported that the Company has completed its contracts with two clinics, DaVita Clinical Research and Dialysis Clinic, Inc., and expects to initiate its U.S. clinical trials this month, beginning with a training phase. The Company recently received unconditional approval for its Investigational Device Exemption application from the Food and Drug Administration to begin a human clinical trial of the Company's OLpur™ H2H™ Hemodiafiltration Module and OLpur™ MD220 Hemodiafilter. Nephros has also obtained the requisite approvals to begin the clinical trials from the Institutional Review Board.

Back to news